Trial Profile
A Phase 1A/1B Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK104 in Subjects With Advanced Solid Tumors
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 24 Oct 2023
Price :
$35
*
At a glance
- Drugs Cadonilimab (Primary)
- Indications Mesothelioma; Solid tumours
- Focus Adverse reactions; First in man
- Acronyms COMPASSION-01
- Sponsors Akesobio Australia
- 19 Oct 2023 According to an Akeso Biopharma media release, data from the study were presented in Cell Reports Medicine, a sub-publication of Cell.
- 19 Oct 2023 Results published in the Akeso Media Release
- 31 Jan 2021 Results of a 64 year-old patient with Large Cell Neuroendocrine Carcinoma of the Lung from this study, presented at the 2020 World Conference on Lung Cancer.